{"PubmedArticle": [{"MedlineCitation": {"OtherID": [], "SpaceFlightMission": [], "KeywordList": [["Autotransfusion", "COVID-19", "Cytokine release syndrome", "Medical ozone", "Ozone gas", "Ozone therapy", "SARS-CoV-2"]], "CitationSubset": ["IM"], "InvestigatorList": [], "OtherAbstract": [], "GeneralNote": [], "PMID": "34186281", "DateCompleted": {"Year": "2021", "Month": "08", "Day": "26"}, "DateRevised": {"Year": "2023", "Month": "11", "Day": "11"}, "Article": {"Language": ["eng"], "ArticleDate": [{"Year": "2021", "Month": "06", "Day": "12"}], "ELocationID": ["10.1016/j.intimp.2021.107874", "S1567-5769(21)00510-5"], "Journal": {"ISSN": "1878-1705", "JournalIssue": {"Volume": "98", "PubDate": {"Year": "2021", "Month": "Sep"}}, "Title": "International immunopharmacology", "ISOAbbreviation": "Int Immunopharmacol"}, "ArticleTitle": "CORonavirus-19 mild to moderate pneumonia Management with blood Ozonization in patients with Respiratory failure (CORMOR) multicentric prospective randomized clinical trial.", "Pagination": {"StartPage": "107874", "MedlinePgn": "107874"}, "Abstract": {"AbstractText": ["Following positive experience on the use of blood ozonation in SARS-CoV-2, the CORMOR randomized trial was designed to evaluate the adjuvant role of oxygen/ozone therapy in mild to moderate SARS-CoV-2 pneumonia.", "The trial (ClinicalTrial.gov NCT04388514) was conducted in four different Italian centers (April-October 2020). Patients were treated according to best available standard of care (SoC) therapy, with or without O3-autohemotherapy (O3-AHT).", "A total of 92 patients were enrolled: SoC\u00a0+\u00a0O3-AHT (48 patients) were compared to the SoC treatment (44 patients). The two groups differed in steroids therapy administration (72.7% in SoC arm vs. 50.0% in O3-AHT arm; p\u00a0=\u00a00.044). Steroid therapy was routinely started when it was subsequently deemed as effective for the treatment of COVID-19 disease. No significant differences in mortality rates, length of hospital stay, mechanical ventilation requirement and ICU admission were observed. Clinical improvement in patients with pneumonia was assessed according to a specifically designed score (decrease in SIMEU class, improvement in radiology imaging, improvement in PaO2/FiO2, reduction in LDH and requirement of oxygen therapy\u00a0\u2264\u00a05\u00a0days). Score assessment was performed on day-3 (T3) and day-7 (TEnd) of O3-AHT treatment. A significant increase in the score was reported at TEnd, in the O3-AHT treatment arm (0 [0-1] in the SoC arm vs. 2 [1-3] the O3-AHT arm; p\u00a0=\u00a00.018). No adverse events related O3-AHT treatment was observed.", "In mild-to-moderate pneumonia due to SARS-CoV-2, adjuvant oxygen/ozone therapy did not show any effect on mortality, or mechanical intubation but show a clinical improvement a day 7 from randomization in a composite clinical endpoint. Larger Randomized prospective studies alone or in combination with steroids are needed to confirm our results."], "CopyrightInformation": "Copyright \u00a9 2021 Elsevier B.V. All rights reserved."}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "U.O. Malattie Infettive, Dipartimento di Medicina dell'Universit\u00e0 di Udine, Universit\u00e0 di Udine e Azienda Sanitaria Universitaria Integrata di Udine, Udine, Italy. Electronic address: emanuela.sozio@gmail.com."}], "LastName": "Sozio", "ForeName": "Emanuela", "Initials": "E"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "SOC Anestesia e Rianimazione 1, Universit\u00e0 di Udine e Azienda Sanitaria Universitaria Integrata di Udine, Udine, Italy. Electronic address: amato.demonte@asufc.sanita.fvg.it."}], "LastName": "De Monte", "ForeName": "Amato", "Initials": "A"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "SOC Anestesia e Rianimazione 1, Universit\u00e0 di Udine e Azienda Sanitaria Universitaria Integrata di Udine, Udine, Italy. Electronic address: giovanni.sermann@asufc.sanita.fvg.it."}], "LastName": "Sermann", "ForeName": "Giovanni", "Initials": "G"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "SOC Anestesia e Rianimazione 2, Universit\u00e0 di Udine e Azienda Sanitaria Universitaria Integrata di Udine, Udine, Italy. Electronic address: flavio.bassi@asufc.sanita.fvg.it."}], "LastName": "Bassi", "ForeName": "Flavio", "Initials": "F"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "U.O. Malattie Infettive, Dipartimento di Medicina dell'Universit\u00e0 di Udine, Universit\u00e0 di Udine e Azienda Sanitaria Universitaria Integrata di Udine, Udine, Italy. Electronic address: sacchet.davide@spes.uniud.it."}], "LastName": "Sacchet", "ForeName": "Davide", "Initials": "D"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "U.O. Lipoapheresis and Center for Inherited Dyslipidemias, Fondazione Toscana Gabriele Monastrio, Via Moruzzi1, Pisa, Italy. Electronic address: francesco.sbrana@ftgm.it."}], "LastName": "Sbrana", "ForeName": "Francesco", "Initials": "F"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Deep Health Unit, Fondazione Toscana \"Gabriele Monasterio\", Pisa, Italy. Electronic address: ripoli@ftgm.it."}], "LastName": "Ripoli", "ForeName": "Andrea", "Initials": "A"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Istituto di Patologia Clinica, Azienda Sanitaria Universitaria Integrata di Udine (ASUID), Udine, Italy. Electronic address: francesco.curcio@asufc.sanita.fvg.it."}], "LastName": "Curcio", "ForeName": "Francesco", "Initials": "F"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Istituto di Patologia Clinica, Azienda Sanitaria Universitaria Integrata di Udine (ASUID), Udine, Italy. Electronic address: martina.fabris@asufc.sanita.fvg.it."}], "LastName": "Fabris", "ForeName": "Martina", "Initials": "M"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "SC di Medicina Interna e Unit\u00e0 di Terapia Semi Intensiva Internistica, Ordine Mauriziano di Torino, Torino, Italy. Electronic address: stefi.marengo@gmail.com."}], "LastName": "Marengo", "ForeName": "Stefania", "Initials": "S"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Ospedale \"Giuseppe Mazzini\" Teramo, Teramo, Italy. Electronic address: danieleitaliani@outlook.it."}], "LastName": "Italiani", "ForeName": "Daniele", "Initials": "D"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "UOC Anestesia e Rianimazione, Clinica Terapia Intensiva, PO San Luca Lucca Lucca, Italy. Electronic address: daliela.boccalatte-rosa@uslnordovest.toscana.it."}], "LastName": "Luciana Boccalatte-Rosa", "ForeName": "Daniela", "Initials": "D"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "U.O. Malattie Infettive, Dipartimento di Medicina dell'Universit\u00e0 di Udine, Universit\u00e0 di Udine e Azienda Sanitaria Universitaria Integrata di Udine, Udine, Italy. Electronic address: carlo.tascini@uniud.it."}], "LastName": "Tascini", "ForeName": "Carlo", "Initials": "C"}, {"Identifier": [], "AffiliationInfo": [], "CollectiveName": "CORMOR study Group"}], "PublicationTypeList": ["Journal Article", "Multicenter Study", "Randomized Controlled Trial"]}, "MedlineJournalInfo": {"Country": "Netherlands", "MedlineTA": "Int Immunopharmacol", "NlmUniqueID": "100965259", "ISSNLinking": "1567-5769"}, "ChemicalList": [{"RegistryNumber": "66H7ZZK23N", "NameOfSubstance": "Ozone"}], "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "Aged"}, {"QualifierName": ["blood", "mortality", "physiopathology", "therapy"], "DescriptorName": "COVID-19"}, {"QualifierName": [], "DescriptorName": "Female"}, {"QualifierName": [], "DescriptorName": "Hospital Mortality"}, {"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": [], "DescriptorName": "Italy"}, {"QualifierName": [], "DescriptorName": "Length of Stay"}, {"QualifierName": ["physiopathology", "virology"], "DescriptorName": "Lung"}, {"QualifierName": [], "DescriptorName": "Male"}, {"QualifierName": [], "DescriptorName": "Middle Aged"}, {"QualifierName": ["administration & dosage", "adverse effects", "blood"], "DescriptorName": "Ozone"}, {"QualifierName": [], "DescriptorName": "Prospective Studies"}, {"QualifierName": [], "DescriptorName": "Respiration, Artificial"}, {"QualifierName": ["blood", "mortality", "physiopathology", "therapy"], "DescriptorName": "Respiratory Insufficiency"}, {"QualifierName": [], "DescriptorName": "Severity of Illness Index"}, {"QualifierName": [], "DescriptorName": "Time Factors"}, {"QualifierName": [], "DescriptorName": "Treatment Outcome"}], "CoiStatement": "The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: [C.T. has received funds for speaking at symposia organized on behalf of Pfizer, Novartis, Merck, Angelini, Zambon, Thermofischer, Biotest, Gilead, Hikma, Biomerieux and Astellas. All other authors: None.]"}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "World Health Organization. Clinical management of severe acute respiratory infection when Novel coronavirus (2019-nCoV) infection is suspected: Interim Guidance. 28 January 2020."}, {"Citation": "Martinez MA. Compounds with therapeutic potential against novel respiratory 2019 coronavirus. Antimicrob Agents Chemother. 2020 Mar 9. pii: AAC.00399-20. doi: 10.1128/AAC.00399-20.", "ArticleIdList": ["PMC7179632", "32152082"]}, {"Citation": "Sweiti H., Ekwunife O., Jaschinski T., Lhachimi S.K. Repurposed Therapeutic Agents Targeting the Ebola Virus: A Systematic Review. Curr. Ther. Res. Clin. Exp. 2017;84:10\u201321.", "ArticleIdList": ["PMC5522984", "28761574"]}, {"Citation": "Chu C.M., Cheng V.C., Hung I.F., et al. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax. 2004;59:252\u2013256.", "ArticleIdList": ["PMC1746980", "14985565"]}, {"Citation": "Liu J., Cao R., Xu M., et al. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discov. 2020;6:16.", "ArticleIdList": ["PMC7078228", "32194981"]}, {"Citation": "Wang M., Cao R., Zhang L., et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro [Letter] Cell Res. 2020;30:269\u2013271.", "ArticleIdList": ["PMC7054408", "32020029"]}, {"Citation": "Yao X., Ye F., Zhang M., et al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Clin. Infect. Dis. 2020", "ArticleIdList": ["PMC7108130", "32150618"]}, {"Citation": "https://www.aifa.gov.it/web/guest/-/azioni-intraprese-per-favorire-la-ricerca-e-l-accesso-ai-nuovi-farmaci-per-il-trattamento-del-covid-19."}, {"Citation": "Tascini C., Sermann G., Pagotto A., et al. Blood ozonization in patients with mild to moderate COVID-19 pneumonia: a single centre experience. Intern. Emerg. Med. 2020:1\u20137. doi: 10.1007/s11739-020-02542-6.", "ArticleIdList": ["10.1007/s11739-020-02542-6", "PMC7603641", "33131033"]}, {"Citation": "Araimo F., Imperiale C., Tordiglione P., et al. Ozone as adjuvant support in the treatment of COVID-19: A preliminary report of probiozovid trial. J. Med. Virol. 2021;93:2210\u20132220.", "ArticleIdList": ["33111980"]}, {"Citation": "Rowen R.J. Ozone therapy as a primary and sole treatment for acute bacterial infection: case report. Med. Gas Res. 2018;8:121\u2013124.", "ArticleIdList": ["PMC6178636", "30319768"]}, {"Citation": "Rowen, et al. Rapid resolution of haemorrhagic fever (EBOLA) in Sierra Leone with ozone therapy. Afr. J. Infect. Dis. 2016;10:49\u201354."}, {"Citation": "Bocci V. Ozonization of blood for the therapy of viral deseases and immunoceficencies. A hypotesis. Medical Hypoteses. 1992;39:30\u201334.", "ArticleIdList": ["1435389"]}, {"Citation": "Elvis A.M. Ozone therapy: a clinical review. J. Nat. Sc. Biol. Med. 2011;2:66\u201370.", "ArticleIdList": ["PMC3312702", "22470237"]}, {"Citation": "Bocci V., Luzzi E., Corradeschi F., Paulesu L., Di Stefano A. Studies on the biological effects of ozone: 3. An attempt to define conditions for optimal induction of cytokines. Lymphokine Cytokine Res. 1993;12:121\u2013126.", "ArticleIdList": ["8324077"]}, {"Citation": "Smith N.L., Wilson A.L., Gandhi J., Vatsia S., Khan S.A. Ozone therapy: an overview of pharmacodynamics, current research, and clinical utility. Med. Gas Res. 2017;7:212\u2013219.", "ArticleIdList": ["PMC5674660", "29152215"]}, {"Citation": "Zamora Z.B., Borrego A., L\u00f3pez O.Y., Delgado R., Gonz\u00e1lez R., Men\u00e9ndez S., et al. Effects of ozone oxidative preconditioning on TNF-\u03b1 release and antioxidant-prooxidant intracellular balance in mice during endotoxic shock. Mediat Inflamm. 2005;2005:16\u201322.", "ArticleIdList": ["PMC1482874", "15770062"]}, {"Citation": "Bocci V: Oxigen Ozone Therapy. A critical Evaluation. Book, Kluver Academic Publishers, 2002."}, {"Citation": "Jiang H.J., Chen N., Shen Z.Q., et al. Inactivation of poliovirus by ozone and the impact of ozone on the viral genome. Biomed. Environ. Sci. 2019;32:324\u2013333.", "ArticleIdList": ["31217049"]}, {"Citation": "Lin Y.C., Wu S.C. Effect of ozone exposure on inactivation of intra and extracellular enterovirus 71. Antiviral Res. 2006;70:147\u2013153.", "ArticleIdList": ["16838411"]}, {"Citation": "Hudson J.B., Sharma M., Petric M. Inactivation of Norovirus by ozone gas in conditions relevant to healthcare. J. Hospital Inf. 2007;10:1\u20136.", "ArticleIdList": ["17350729"]}, {"Citation": "Shin G.A., Sobsey M.D. Reduction of Norwalk virus, Poliovirus1 and Bacteriophage M52 by ozone disinfection in water. Appl. Environ. MIcrobiol. 2003;69:3975\u20133978.", "ArticleIdList": ["PMC165156", "12839770"]}, {"Citation": "Izadi M., Cegolon L., Javanbakht M., et al. Ozone therapy for the treatment of COVID-19 pneumonia: A scoping review. Int. Immunopharmacol. 2021 doi: 10.1016/j.intimp.2020.107307.", "ArticleIdList": ["10.1016/j.intimp.2020.107307", "PMC7752030", "33476982"]}, {"Citation": "Zhou M. Ozone: A powerful weapon to combat COVID-19 outbreak http://www.china.org.cn/opinion/2020-02/26/content_75747237.htm."}, {"Citation": "https://www.simeu.it/w/articoli/leggiArticolo/3964/leggi."}, {"Citation": "RECOVERY Collaborative Group, Horby P., Lim W.S., Emberson J.R., et al. Dexamethasone in Hospitalized Patients with Covid-19 - Preliminary Report. N. Engl. J. Med. 2020 doi: 10.1056/NEJMoa2021436.", "ArticleIdList": ["10.1056/NEJMoa2021436", "PMC7383595", "32678530"]}, {"Citation": "https://www.aifa.gov.it/documents/20142/1123276/Corticosteroidi_06.10.2020.pdf/075c9302-895c-4d7e-11bc-0e2319082ffc."}, {"Citation": "R Core Team. R: a language and environment for statistical computing. R Foundation for Statistical Computing. Vienna, Austria, 2019."}, {"Citation": "Cattel F., Giordano S., Bertiond C., Lupia T., Corcione S., Scaldaferri M., Angelone L., De Rosa F.G. Ozone therapy in COVID-19: A narrative review. Virus Res. 2021 Jan;2(291):198207.", "ArticleIdList": ["PMC7585733", "33115670"]}, {"Citation": "Menendez-Cepero S., Marques-Magallanes-Regojo J.A., Hernandez-Martinez A., Tall\u00f3n F.J.H., Baeza-Noci J. Therapeutic effects of Ozone therapy that justifies its use for the treatment of COVID-19. Research Open. J. Neurol. 2020;3:1\u20136."}, {"Citation": "Mart\u00ednez-S\u00e1nchez G., Schwartz A., Di Donna V. Potential Cytoprotective Activity of Ozone Therapy in SARS-CoV-2/COVID-19. Antioxidants (Basel). 2020;9:389.", "ArticleIdList": ["PMC7278582", "32384798"]}, {"Citation": "De Monte A., Sermann G., Sozio E., Sbrana F., Tascini C. Blood ozonization in patients with mild to moderate COVID-19 pneumonia: a single Centre experience \u2013 reply. Intern. Emerg. Med. 2021", "ArticleIdList": ["PMC7603641", "33131033"]}, {"Citation": "Fern\u00e1ndez-Cuadros M.E., Albaladejo-Flor\u00edn M.J., Pe\u00f1a-Lora D., \u00c1lava-Rabasa S., Susana P\u00e9rez-Moro O. Ozone (O3) and SARS-CoV-2: Physiological Bases and Their Therapeutic Possibilities According to COVID-19 Evolutionary Stage. SN Compr. Clin. Med. 2020 doi: 10.1007/s42399-020-00328-7.", "ArticleIdList": ["10.1007/s42399-020-00328-7", "PMC7340747", "32838159"]}, {"Citation": "Hern\u00e1ndez A., Vi\u00f1als M., Pablos A., Vil\u00e1s F., Papadakos P.J., Wijeysundera D., Bergese S.D., Vives M. Ozone therapy for patients with COVID-19 pneumonia: a preliminary report of a prospective case-control study. Int. Immunopharmacol. 2021 doi: 10.1016/j.intimp.2020.107261.", "ArticleIdList": ["10.1016/j.intimp.2020.107261", "PMC7833586", "33310665"]}, {"Citation": "Franzini M., Valdenassi L., Ricevuti G., Chirumbolo S., Depfenhart M., Bertossi D., Tirelli U. Oxygen-ozone (O2\u2013O3) immunoceutical therapy for patients with COVID-19, Preliminary evidence reported. Int. Immunopharmacol. 2020;88:106879. doi: 10.1016/j.intimp.2020.106879.", "ArticleIdList": ["10.1016/j.intimp.2020.106879", "PMC7414302", "32795898"]}, {"Citation": "Younis N.K., Zareef R.O., Al Hassan S.N., et al. Hydroxychloroquine in COVID-19 Patients: Pros and Cons. Front. Pharmacol. 2020;11:597985.", "ArticleIdList": ["PMC7751757", "33364965"]}, {"Citation": "Schwartz A., Mart\u00ednez-S\u00e1nchez G., Menassa de Luc\u00eda A., Mej\u00eda Viana S., Alina Mita C. Complementary Application of the Ozonized Saline Solution in Mild and Severe Patients with Pneumonia Covid-19: A Non-randomized Pilot Study. Preprints. 2020 2020060233."}, {"Citation": "Fern\u00e1ndez-Cuadros M.E., Albaladejo-Flor\u00edn M.J., \u00c1lava-Rabasa S., Usandizaga-Elio I., Martinez-Quintanilla Jimenez D., Pe\u00f1a-Lora D., Neira-Borrajo I., L\u00f3pez-Mu\u00f1oz M.J., Rodr\u00edguez-de-C\u00eda J., P\u00e9rez-Moro O.S. Effect of Rectal Ozone (O 3) in Severe COVID-19 Pneumonia: Preliminary Results. SN Compr. Clin. Med. 2020 doi: 10.1007/s42399-020-00374-1.", "ArticleIdList": ["10.1007/s42399-020-00374-1", "PMC7397966", "32838181"]}, {"Citation": "Fern\u00e1ndez-Cuadros M.E., Albaladejo-Flor\u00edn M.J., \u00c1lava-Rabasa S., Gallego-Galiana J., P\u00e9rez-Cruz J.F., Usandizaga-Elio I., Pacios E., Torres-Garc\u00eda D.E., Pe\u00f1a-Lora D., Casique-Bocanegra L., L\u00f3pez-Mu\u00f1oz M.J., Rodr\u00edguez-de-C\u00eda J., P\u00e9rez-Moro O.S. Compassionate Use of Rectal Ozone (O 3) in Severe COVID-19 Pneumonia: a Case-Control Study. SN Compr. Clin. Med. 2021 doi: 10.1007/s42399-021-00849-9.", "ArticleIdList": ["10.1007/s42399-021-00849-9", "PMC7984736", "33778374"]}, {"Citation": "https://www.epicentro.iss.it/en/coronavirus/bollettino/Report-COVID-2019_28_april_2021.pdf."}], "ReferenceList": []}], "History": [{"Year": "2021", "Month": "3", "Day": "15"}, {"Year": "2021", "Month": "6", "Day": "9"}, {"Year": "2021", "Month": "6", "Day": "9"}, {"Year": "2021", "Month": "6", "Day": "30", "Hour": "6", "Minute": "0"}, {"Year": "2021", "Month": "8", "Day": "27", "Hour": "6", "Minute": "0"}, {"Year": "2021", "Month": "6", "Day": "29", "Hour": "20", "Minute": "16"}, {"Year": "2021", "Month": "6", "Day": "12"}], "PublicationStatus": "ppublish", "ArticleIdList": ["34186281", "PMC8196321", "10.1016/j.intimp.2021.107874", "S1567-5769(21)00510-5"]}}], "PubmedBookArticle": []}